Thalidomide is an oral drug marketed in the 1950s as a sedative and an anti-emetic during pregnancy that was removed from the market when its teratogenic side effects appeared in new born children due to inadequate tests to assess the drug's safety. Recent studies evaluating the use of thalidomide in cancer and HIV diseases have sparked renewed interest. The electrochemical behavior of thalidomide on a glassy c...
Glivec is a relatively small molecule with activity against the protein tyrosine kinase, a protein expressed by all patients with chronic myelogenous leukemia (CML). Based on its activity on CML, glivec is undergoing extensive evaluation of its activity against other types of tumor. As a result, there is an ongoing need for clarification of glivec pharmacokinetics so that issues such as drug-biomolecular comple...
Glivec is a newly developed drug that belongs to the class of 2-phenylaminopyrimidine. It is a potent inhibitor of ABL-kinase, the main clinical manifestation of chronic myelogenous leukemia (CML). Based on its activity on CML, glivec is undergoing extensive evaluation for its activity against other tumor types. Detection and quantitation of glivec in biological fluids or cells is thus very important. The antil...
The electrochemical behavior of the antileukemia drug glivec was investigated at a glassy carbon electrode (GCE). The oxidation is a complex, pH-dependent, irreversible electrode process involving the transfer of 2 electrons and 2 protons and the formation of an electroactive product, Pglivec, which strongly adsorbs on the GCE surface and undergoes reversible oxidation. The adsorption of Pglivec at the GCE surf...
Financiadores do RCAAP | |||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |